Skip to main content

DNB Bioteknologi

DNB Bioteknologi is an equity fund managed by DNB in the Industri – Bioteknologi category.

About this fund

Categorised as Industri – Bioteknologi, DNB Bioteknologi is an equity fund from DNB.

Measured on return so far this year measured in NOK as of 13.11.2026, the fund is number 4 of 4 in its category.

Benedicte Kilander Bakke has been on the fund since 2020.

Tracking error against its benchmark is 9.9%.

Launched in 2020, it has 6 years behind it.

The manager states a volatility of 23.2% for the fund.

Manager
DNB
Category
Industri – Bioteknologi
Region
Global
Sector
Health Care
Style
Sector Focus
SFDR
Article 8
ISIN
NO0010877707
Inception
2020-05-05
Benchmark
Nasdaq Biotechnology Index
AUM
379 m NOK
Returns
YTD 2.2% · 1Y 10.8% · 3Y 10.8% · 5Y 7.8%

Portfolio managers

Actively managedEquityGlobalHealth care
YTD Return · NOK
+2,2 %
The class started 05.05.2020. 10 years does not exist yet; the figure above is since launch, annualised (as of 13.11.2026).
NOK class A
Last NAV 151,68 NOK · 13 Nov 2026
Returns by period · NOK · net
ann. 3Y+
+2,2 %
YTD
+10,8 %
1y
+10,8 %
3y, annualised
+7,8 %
5y, annualised
Fund size
379,5 mill. NOK
Total fund AUM
Management fee
0,85 %
Annual · class A · 0,30 %–1,20 % across 5 share classes
Ongoing charge
0,85 %
Annual · class A
Performance fee
None
Stated by the manager
Annual cost on platforms
1,10 %–1,45 %
Class A · 9 platforms · net of platform rebate, incl. platform fee, excl. transaction costs
SFDR
Article 8
Sustainability
Launched
May 2020
ISIN NO0010877707
BenchmarkNasdaq Biotechnology
Fund website
Risk
Volatility (stated by the manager)23,2 %
Sharpe Ratio0,22
Max Drawdown−27,8 %
Beta1,02
Info Ratio−0,91
Tracking Error9,9 %
ESG Score5,4
About the fund
The fund

DNB Bioteknologi is an actively managed global equity fund with a track record back to 2020. The management company is DNB Asset Management in Oslo, the fund arm of DNB, Norway's largest bank. The company is indirectly wholly owned by DNB Bank ASA.

Investment philosophy

The mandate is broader than pure biotechnology companies. The fund may invest in biotechnology, diagnostics, pharma, biological drugs including gene therapy and other health-related businesses. It may also invest in companies where only part of the business is tied to health.

The managers

Benedicte Kilander Bakke is the lead manager. She and Rune Sand-Holm have managed the fund since May 2020. Bakke trained as a dentist, holds an MBA from NHH, has a background in the pharmaceutical industry and became a portfolio manager at DNB in 2018. Sand-Holm has a background as an analyst covering shipping, real estate and construction. Anesa Mulabecirovic Sahnoun became a manager in May 2026, after being an analyst on the fund since June 2021. She holds a doctorate in medicine and has worked as a physician and as an investment analyst at Hadean Ventures. The managers are based in Oslo and are part of DNB Asset Management's health care team, which also manages DNB Health Care, where Sand-Holm is lead manager, and DNB Fund Women's Health, launched in August 2026 with Mulabecirovic Sahnoun as lead manager.

The portfolio

The portfolio holds a limited number of companies, and a large share of it sits in large companies. Steady top positions include Argenx, UCB, BioMarin Pharmaceutical, Neurocrine Biosciences and Axsome Therapeutics. The US is the persistent largest country, but European companies such as Argenx and UCB also recur.

FundTelligence description · 24/10/2026
Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

Portfolio managers

BE
Portfolio Manager
On the fund since May 5, 2020
AN
Portfolio Manager
On the fund since May 1, 2026
RU
Portfolio Manager
On the fund since May 5, 2020

Position in the peer group

Industry Biotechnology Equities · 6 funds in the peer group. The number ranked and the date are stated per period. 3 of them converted to NOK.

2 of 4 funds ranked on a calculated return

#4/ 4Year to date
+2.24% NOK

as of 13 Nov 2026 · NOK class

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#4/ 41 year
+10.75% NOK

as of 13 Nov 2026 · NOK class

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#4/ 43 years (ann.)
+10.83% NOK

as of 13 Nov 2026 · NOK class

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

#4/ 45 years (ann.)
+7.77% NOK

as of 13 Nov 2026 · NOK class

About the figures

2 of 6 funds in the group hold no figure for the date and are not counted. 3 funds with older figures: up to 5 business days.

Comparison basis

Year to date

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 share class outside the rule, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

1 year

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

3 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

5 years (ann.)

Comparison basis: Ranked among 4 of 6 funds · 2 left out (1 return as of an earlier date, 1 return without a stated date) · returns as of 13 Nov 2026–16 Nov 2026

The positions describe historical return and are not an assessment of the fund, nor investment advice. Past performance is no guarantee of future returns. A position applies only within its own peer group and cannot be compared with positions in other peer groups.

Fund data is taken from the managers’ own reports, otherwise computed from NAV history and, as a last resort, taken from distributor listings. Not official figures; verify with the fund provider before investing.

About our data